Toll-like receptor 4 on islet β cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes

Experimental and Molecular Medicine

Volumn 44, Issue 4, 2012, Pages 260-267

  Li, Min ^a   Song, Lujun ^a   Gao, Xiaodong ^a   Chang, Wenju ^a   Qin, Xinyu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Diabetes mellitus; HMGB1 protein; Inbred NOD; Islets of langerhans; Mice; Toll like receptor 4; Type 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 ANTIBODY; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTIBODY; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BINDING AND RELATED PHENOMENA; CELL SURFACE BINDING; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

MUS;

EID: 84860539468     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2012.44.4.021     Document Type: Article

References (26)

1. Abdulahad DA, Westra J, Limburg PC, Kallenberg C, Bijl M. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev 2010;9: 661-665
2. Anderson MS, Bluestone JA. The NOD mouse: A model of immune dysregulation. Annu Rev Immunol 2005;23:447-485
3. Devaraj S, Tobias P, Jialal I. Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokines 2011;55:441-445
4. Gdynia G, Keith M, Kopitz J, Bergmann M, Fassl A, Weber AN, George J, Kees T, Zentgraf HW, Wiestler OD, Schirmacher P, Roth W. Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Res 2010;70: 8558-8568
5. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004;173:2280-2287
6. Grieco FA, Vendrame F, Spagnuolo I, Dotta F. Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol 2011;33:57-66
7. Han J, Zhong J, Wei W, Wang Y, Huang Y, Yang P, Purohit S, Dong Z, Wang MH, She JX, Gong F, Stern DM, Wang CY. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008;57:2118-2127
8. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003;23:15-44
9. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. Mol Med 2008;14:476-484
10. Li M, Song L, Qin X. Glycan changes: cancer metastasis and anti-cancer vaccines. J Biosci 2010;35:665-673
11. Lin Q, Fang J, Fang D, Li B, Zhou H, Su SB. Production of recombinant human HMGB1 and anti-HMGB1 rabbit serum. Int Immunopharmacol 2011a;11:646-651
12. Lin Q, Yang XP, Fang D, Ren X, Zhou H, Fang J, Liu X, Zhou S, Wen F, Yao X, Wang JM, Su SB. High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis. Arterioscler Thromb Vasc Biol 2011b;31:1024-1032
13. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB) Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-342
14. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449:819-826
15. Meyers AJ, Shah RR, Gottlieb PA, Zipris D. Altered toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med (Berl) 2010;88:1221-1231
16. Miranda-Hernandez S, Gerlach N, Fletcher JM, Biros E, Mack M, Korner H, Baxter AG. Role for MyD88, TLR2 and TLR9 but Not TLR1, TLR4 or TLR6 in Experimental Autoimmune Encephalomyelitis. J Immunol 2011;187: 791-804
17. Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 2011;15: 1023-1035
18. Pino SC, Kruger AJ, Bortell R. The role of innate immune pathways in type 1 diabetes pathogenesis. Curr Opin Endocrinol Diabetes Obes 2010;17:126-130
19. Song JS, Kang CM, Park CK, Yoon HK, Lee SY, Ahn JH, Moon HS. Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-beta-induced alveolar epithelial to mesenchymal transition. Exp Mol Med 2011;43: 517-524
20. Sutton R, Peters M, Mcshane P, Gray D, Morris PJ. Isolation of rat pancreatic-islets by ductal injection of collagenase. Transplantation 1986;42:689-691
21. Van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-99
22. Wang F, Lu Z, Hawkes M, Yang H, Kain KC, Liles WC. Fas (CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from macrophages. J Inflamm (Lond) 2010;7:30
23. Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal-proteins hmg-1 and hmg-2 in sera of patients with juvenile rheumatoid-arthritis. Arthritis Rheum 1990;33:1378-1383
24. Yaacob NS, Kaderi MA, Norazmi MN. Differential transcriptional expression of PPAR alpha, PPAR gamma 1, and PPAR gamma 2 in the peritoneal macrophages and T-cell subsets of non-obese diabetic mice. J Clin Immunol 2009;29:595-602
25. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006;26:174-179
26. Zhang CC, Krieg S, Shapiro DJ. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol Endocrinol 1999;13:632-643